Filed pursuant to Rule 424(b)(3)
Registration No. 333-266741
SUPPLEMENT NO 1. DATED March 3, 2025
TO
PROSPECTUS SUPPLEMENT DATED August 17, 2022
(To Prospectus Dated August 17, 2022)
Tenaya Therapeutics, Inc.
This Supplement No. 1 to Prospectus Supplement (this “Supplement”) supplements and amends the Prospectus Supplement dated
August 17, 2022 (the “Prospectus Supplement”). This Supplement should be read in conjunction with the Prospectus Supplement and the accompanying Prospectus dated August 17, 2022 (the “Prospectus”). This Supplement is
qualified by reference to the Prospectus Supplement, except to the extent that the information presented herein supersedes the information contained in the Prospectus Supplement.
On August 10, 2022, we entered into a Sales Agreement (the “Sales Agreement”) with Leerink Partners LLC (“Leerink
Partners”) relating to shares of our common stock offered by the Prospectus Supplement and the accompanying Prospectus. In accordance with the terms of the Sales Agreement, we may offer and sell shares of our common stock having an aggregate
offering price of up to $75,000,000 from time to time through Leerink Partners, acting as our sales agent, pursuant to at-the-market transactions (the “ATM”).
As of the date of this Supplement, we have sold an aggregate of 1,358,333 shares of our common stock pursuant to the Sales Agreement for aggregate gross proceeds of approximately $5.2 million.
The purpose of this Supplement is to suspend the ATM and to terminate the continuous offering by us under the Prospectus Supplement, effective
on March 3, 2025. We will not make any sales of our common stock pursuant to the Sales Agreement unless and until a new prospectus supplement is filed with the Securities and Exchange Commission; however, the Sales Agreement remains in full
force and effect.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities
or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.
The date of
this Supplement No. 1 to Prospectus Supplement is March 3, 2025.
